These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 23689905)

  • 21. Defining the complement biomarker profile of C3 glomerulopathy.
    Zhang Y; Nester CM; Martin B; Skjoedt MO; Meyer NC; Shao D; Borsa N; Palarasah Y; Smith RJ
    Clin J Am Soc Nephrol; 2014 Nov; 9(11):1876-82. PubMed ID: 25341722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C3 glomerulopathy and current dilemmas.
    Ito N; Ohashi R; Nagata M
    Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of C3 Glomerulopathy in Adult Kidney Transplant Recipients: A Systematic Review.
    Gonzalez Suarez ML; Thongprayoon C; Hansrivijit P; Kovvuru K; Kanduri SR; Aeddula NR; Pivovarova AI; Chewcharat A; Bathini T; Mao MA; Basu A; Cheungpasitporn W
    Med Sci (Basel); 2020 Oct; 8(4):. PubMed ID: 33096866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?
    Alexander MP; Fervenza FC; De Vriese AS; Smith RJH; Nasr SH; Cornell LD; Herrera Hernandez LP; Zhang Y; Sethi S
    J Nephrol; 2016 Apr; 29(2):203-209. PubMed ID: 26187133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treating C3 glomerulopathy with eculizumab.
    Welte T; Arnold F; Kappes J; Seidl M; Häffner K; Bergmann C; Walz G; Neumann-Haefelin E
    BMC Nephrol; 2018 Jan; 19(1):7. PubMed ID: 29329521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eculizumab in Pediatric Dense Deposit Disease.
    Oosterveld MJ; Garrelfs MR; Hoppe B; Florquin S; Roelofs JJ; van den Heuvel LP; Amann K; Davin JC; Bouts AH; Schriemer PJ; Groothoff JW
    Clin J Am Soc Nephrol; 2015 Oct; 10(10):1773-82. PubMed ID: 26316621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. C3 glomerulonephritis and systemic lupus erythematosus: A report of a patient treated with eculizumab and review of the literature.
    Fernandez-Ruiz R; Blank RB; Wu M; Belmont HM
    Lupus; 2021 Sep; 30(10):1671-1678. PubMed ID: 34192954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eculizumab in post-transplant C3 glomerulonephritis caused by a C3 mutation
.
    Kim JS; Foster KW; Westphal SG
    Clin Nephrol; 2020 Jan; 93(1):51-56. PubMed ID: 31661064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment options for C3 glomerulopathy.
    Nester CM; Smith RJ
    Curr Opin Nephrol Hypertens; 2013 Mar; 22(2):231-7. PubMed ID: 23318699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eculizumab for treatment of rapidly progressive C3 glomerulopathy.
    Le Quintrec M; Lionet A; Kandel C; Bourdon F; Gnemmi V; Colombat M; Goujon JM; Frémeaux-Bacchi V; Fakhouri F
    Am J Kidney Dis; 2015 Mar; 65(3):484-9. PubMed ID: 25530108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
    Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
    Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. C3 glomerulopathy.
    Servais A; Noël LH; Frémeaux-Bacchi V; Lesavre P
    Contrib Nephrol; 2013; 181():185-93. PubMed ID: 23689580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies.
    McCaughan JA; O'Rourke DM; Courtney AE
    Am J Transplant; 2012 Apr; 12(4):1046-51. PubMed ID: 22233157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.
    Noris M; Galbusera M; Gastoldi S; Macor P; Banterla F; Bresin E; Tripodo C; Bettoni S; Donadelli R; Valoti E; Tedesco F; Amore A; Coppo R; Ruggenenti P; Gotti E; Remuzzi G
    Blood; 2014 Sep; 124(11):1715-26. PubMed ID: 25037630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype.
    Ravindran A; Fervenza FC; Smith RJH; Sethi S
    Kidney Int; 2018 Jul; 94(1):178-186. PubMed ID: 29729982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics and outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy in Japanese children.
    Ueda C; Horinouchi T; Inoki Y; Ichikawa Y; Tanaka Y; Kitakado H; Kondo A; Sakakibara N; Nagano C; Yamamura T; Fujimura J; Kamiyoshi N; Ishimori S; Ninchoji T; Kaito H; Shima Y; Iijima K; Nozu K; Yoshikawa N
    Pediatr Nephrol; 2024 Sep; 39(9):2679-2689. PubMed ID: 38662234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children.
    Okuda Y; Ishikura K; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Fukuzawa R; Ogata K; Honda M
    Nephrology (Carlton); 2015 Apr; 20(4):286-92. PubMed ID: 25524631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum.
    Al-Ghaithi B; Chanchlani R; Riedl M; Thorner P; Licht C
    Pediatr Nephrol; 2016 Nov; 31(11):2079-86. PubMed ID: 27008643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of C3 glomerulopathy with complement blockers.
    Vivarelli M; Emma F
    Semin Thromb Hemost; 2014 Jun; 40(4):472-7. PubMed ID: 24799307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological features of C3 glomerulopathy in children: a single-center experience.
    Drake KA; Ellington N; Gattineni J; Torrealba JR; Hendricks AR
    Pediatr Nephrol; 2020 Jan; 35(1):153-162. PubMed ID: 31667615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.